3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Breast
1
Conditions
Lung Neoplasms
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Respiratory Aspiration
1
Radiation Pneumonitis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Papillomavirus Infections
1
Lymphangioleiomyomatosis
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Deglutition Disorders
1
Central Nervous System Neoplasms
1
Carcinoma in Situ
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Interventions
pembrolizumab
88
Carboplatin
77
Specimen Handling
76
Magnetic Resonance Spectroscopy
63
Pemetrexed
59
Cisplatin
47
durvalumab
44
Paclitaxel
38
Nivolumab
34
atezolizumab
32
osimertinib
29
Radiotherapy
29
Radiosurgery
29
Biopsy
26
Blood Specimen Collection
25
Gemcitabine
24
Docetaxel
24
Immunoglobulin G
23
Disulfides
22
Standard of Care
21
Drug Therapy
21
Etoposide
19
Taxes
18
Practice Guidelines as Topic
18
Radiation
17
Educational Status
16
130-nm albumin-bound paclitaxel
15
X-Rays
14
Surveys and Questionnaires
14
Bevacizumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Respiratory Function Tests
×
1 year
×
Clear all
NCT06925295
2026-01-02
(XeRTLC)
University of Iowa
Phase 2
Recruiting
15 enrolled
NCT02735746
2025-08-22
HFFLI
Cedars-Sinai Medical Center
Completed
60 enrolled